Bartosz Mroczyk
Research Subjects
Bartosz Mroczyk has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Gąsecka
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Grzegorz Procyk
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Jakub Michal Zimodro
1st Chair and Department of Cardiology, Medical University of Warsaw, Poland
1 shared publication - Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
1 shared publication - Michal Lis
Department of Internal Medicine, Endocrinology, Diabetology, Nephrology and Metabolic Diseases, Czerniakowski Hospital, 00-739 Warsaw, Poland
1 shared publication - Olivia Wasilewska
Clinical Department of Internal Medicine, Endocrinology, Diabetology and Nephrology, Czerniakowski Hospital, Poland
1 shared publication
Latest Publications
- Open Access
- 20 October 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2246-2257
Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.
- 20 October 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2246-2257
Open AccessIncorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.